Erika P. Hamilton, MD
Patients with HER2-positive breast cancer no longer have as poor of a prognosis due to the development of numerous HER2-directed therapies, explains Erika P. Hamilton, MD.
, Hamilton, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discussed recent FDA approvals in the treatment paradigm of HER2-positive breast cancer and shed light on the prevalence of brain metastases.
OncLive: If a patient undergoes testing and it comes back that they have HER2 expression, what are some of the first things you are thinking about when determining treatment?
: We know that HER2-positive breast cancers are more aggressive and tend to grow quicker. However, we now have HER2-directed therapies that make this disease not as poor of a prognosis as it used to be. In many ways, we all dread triple-negative breast cancer much more than HER2-positive breast cancer now, with the advent of improved HER2-targeted agents that have improved outcomes significantly.
... to read the full story